BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26408743)

  • 1. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
    Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
    Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
    Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
    Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy.
    Sato N; Shiota M; Shiga KI; Kashiwagi E; Takeuchi A; Inokuchi J; Yokomizo A; Naito S; Eto M
    Cancer Invest; 2020 Nov; 38(10):559-564. PubMed ID: 33016145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
    Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
    BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
    Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
    J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
    J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
    Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
    Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.